 Efficacy ICS novel receptor antagonist prevention migraine attacks complex answer simple question ICS Migraine Study Group novel potent selective receptor antagonist ICS migraine attacks randomized double-blind placebo-controlled multicentre international trials total patients classic common migraine trials parallel-group design month baseline observation months treatment similar results primary efficacy parameter proportional reduction attack frequency months treatment Twenty-two patients trials efficacy Mild constipation patients active treatment None doses ICS mg mg mg result attack frequency placebo confidence intervals difference effect placebo wide mg ICS reduction attack frequency unusual finding efficacy parameters results dose mg results dose mg intermediate effect mg inverse relation dose efficacy bell-shaped dose-response curve mg effective present study inconclusive intriguing results doses definite conclusion efficacy ICS prophylactic treatment migraine